Corticosteroids for treating nerve damage in leprosy

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Van Veen, Natasja H J ^a   Nicholls, Peter G ^b   Smith, W Cairns S ^c   Richardus, Jan Hendrik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; SODIUM CHLORIDE; GLUCOCORTICOID;

CATARACT; CORTICOSTEROID THERAPY; CUBITAL TUNNEL SYNDROME; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; LEPROSY; LONG TERM CARE; LOW DRUG DOSE; MOTOR NERVE; NERVE DECOMPRESSION; NERVE FUNCTION; NERVE INJURY; NEUROPATHIC PAIN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NERVE; SYSTEMATIC REVIEW; TREATMENT DURATION; ULCER; ULNAR NERVE; VISUAL ANALOG SCALE; COMPLICATION; META ANALYSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; SOMATOSENSORY DISORDERS;

GLUCOCORTICOIDS; HUMANS; LEPROSY; METHYLPREDNISOLONE; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOSENSORY DISORDERS;

EID: 84970024082     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005491.pub3     Document Type: Review

References (63)

1. Garbino JA, Virmond Mda C, Ura S, Salgado MH, Naafs B. A randomized clinical trial of oral steroids for ulnar neuropathy in type 1 and type 2 leprosy reactions [Ensaio clínico sobre o tratamento com esteróides via oral da neuropatia ulnar em reação tipo 1 e tipo 2 da hanseníase]. Arquivos de Neuro-Psiquiatria 2008;66(4):861-7.
2. Sundar Rao PSS, Sugamaran DST, Richard J, Smith WCS. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Leprosy Review 2006;77(1):25-33. [PUBMED: 16715687]
3. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Leprosy Review 2003;74(4):311-8. [PUBMED: 14750576 ]
4. Van Brakel WH, Anderson AM, Withington SG, Croft RP, Nicholls PG, Richardus JH, et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Leprosy Review 2003;74(4):300-10. [PUBMED: 14750575]
5. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Macdonald M, Mahat K, et al. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Neglected Tropical Diseases 2011;5(4):e1041. [PUBMED: 21532737]
6. Boucher P, Millan J, Parent M, Moulia-Pela JP. Randomized controlled trial of medical and medico-surgical treatment of Hansen's neuritis [Essai compare randomise du traitement medical et medico-chirurgical des nevrites hanseniennes]. Acta Leprologica 1999;11(4):171-7.
7. Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Leprosy Review 2000;71(2):154-68.
8. Dandapat MC, Sahu DM, Mukherjee LM, Panda C, Baliarsing AS. Treatment of leprous neuritis by neurolysis combined with perineural corticosteroid injection. Leprosy Review 1991;62(1):27-34.
9. Ebenezer M, Andrews P, Solomon S. Comparative trial of steroids and surgical intervention in the management of ulnar neuritis. International Journal of Leprosy and Other Mycobacterial Diseases 1996;64(3):282-6.
10. Jardim MR, Illarramendi X, Nascimento OJ, Nery JA, Sales AM, Sampaio EP, et al. Pure neural leprosy: steroids prevent neuropathy progression. Arquivos de Neuropsiquiatria 2007;65(4A):969-73.
11. Lambert SM, Lockwood DN. A randomised double blind controlled trial comparing ciclosporin and prednisolone in the treatment of new leprosy type 1 reactions. Email to DN Lockwood, London School of Hygiene & Tropical Medicine (sent on 4 August 2014).
12. Lockwood DN. Azathioprine in the treatment of leprosy reactions. Email to DN Lockwood, London School of Hygiene & Tropical Medicine (sent on 4 August 2014).
13. Marlowe SN, Hawksworth RA, Butlin CR, Nicholls PG, Lockwood DN. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Transactions of the Royal Society of Tropical Medicine and Hygiene 2004;98(10):602-9.
14. Marlowe SN, Leekassa R, Bizuneh E, Knuutilla J, Ale P, Bhattarai B, et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007;101(10):1004-12.
15. Pannikar VK, Ramprasad S, Reddy NR, Andrews P, Ravi K, Fritschi EP. Effect of epicondylectomy in early ulnar neuritis treated with steroids. International Journal of Leprosy and Other Mycobacterial Diseases 1984;52(4):501-5.
16. Smith WC, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls PG, Richardus JH. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 2004;328(7454):1459.
17. Wilder-Smith A, Wilder-Smith E. Effect of steroid therapy on parameters of peripheral autonomic dysfunction in leprosy patients with acute neuritis. International Journal of Leprosy and Other Mycobacterial Diseases 1997;65(1):20-7.
18. Anderson AM, Croft RP. Reliability of Semmes Weinstein monofilament and ballpoint sensory testing, and voluntary muscle testing in Bangladesh. Leprosy Review 1999;70(3):305-13.
19. Becx-Bleumink M, Berhe D, Mannetje W. The management of nerve damage in the leprosy control services. Leprosy Review 1990;61(1):1-11.
20. Bell-Krotoski JA. "Pocket filaments" and specifications for the Semmes-Weinstein monofilaments. Journal of Hand Therapy 1990;3:26-31.
21. Brandsma W. Basic nerve function assessment in leprosy patients. Leprosy Review 1981;52(2):161-70.
22. Britton WJ. The management of leprosy reversal reactions. Leprosy Review 1998;69(3):225-34.
23. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. Journal of Internal Medicine 1994;236:619-32.
24. Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Leprosy Review 1999;70(2):140-59.
25. Heijnders ML. The dynamics of stigma in leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 2004;72(4):437-47.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. The International Federation of Anti-Leprosy Associations (ILEP). How to Diagnose and Treat Leprosy. London: ILEP, 2001.
28. The International Federation of Anti-Leprosy Associations (ILEP). How to Recognise and Manage Reactions. London: ILEP, 2002.
29. Job CK. Nerve damage in leprosy. International Journal of Leprosy and Other Mycobacterial Diseases 1989;57(2):532-9.
30. Koelewijn LF, Meima A, Broekhuis SM, Richardus JH, Mitchell PD, Benbow C, et al. Sensory testing in leprosy: comparison of ballpoint pen and monofilaments. Leprosy Review 2003;74(1):42-52.
31. Leekassa R, Bizuneh E, Alem A. Prevalence of mental distress in the outpatient clinic of a specialized leprosy hospital. Addis Ababa, Ethiopia, 2002. Leprosy Review 2004;75(4):367-75.
32. Lienhardt C, Fine PEM. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation?. Leprosy Review 1994;65(1):9-33.
33. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infection and Immunity 2001;69(5):3413-7.
34. Lockwood DN, Vinayakumar S, Stanley JN, McAdam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. International Journal of Leprosy and Other Mycobacterial Diseases 1993;61(1):8-15.
35. Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Leprosy Review 2000;71(Supplement):S111-4.
36. Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bulletin of the World Health Organization 2005;83(3):230-5.
37. Naafs B, Pearson JM, Wheate HW. Reversal reaction: the prevention of permanent nerve damage. Comparison of short and long-term steroid treatment. International Journal of Leprosy and Other Mycobacterial Diseases 1979;47(1):7-12.
38. Naafs B. Treatment of reactions and nerve damage. International Journal of Leprosy and Other Mycobacterial Diseases 1996;64(4 Supplement):S21-8.
39. Naafs B. Treatment duration of reversal reaction: a reappraisal. Back to the past. Leprosy Review 2003;74(4):328-36.
40. Nicholls PG, Croft RP, Richardus, JH, Withington SG, Smith WC. Delay in presentation, an indicator for nerve function status at registration and for treatment outcome - the experience of the Bangladesh Acute Nerve Damage Study cohort. Leprosy Review 2003;74(4):349-56.
41. Pearson JM. The use of corticosteroids in leprosy. Leprosy Review 1981;52(4):293-8.
42. Pearson JMH. The evaluation of nerve damage in leprosy. Leprosy Review 1982;53(2):119-30.
43. Rafferty J. Curing the stigma of leprosy. Leprosy Review 2005;76(2):119-26.
44. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
45. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, Van Brakel WH, et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Leprosy Review 2003;74(4):319-27.
46. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. International Journal of Leprosy and Other Mycobacterial Diseases 1966;34(3):255-73.
47. Rose P, Waters MF. Reversal reactions in leprosy and their management. Leprosy Review 1991;62(2):113-21.
48. SALSA Collaborative Study Group. The development of a short questionnaire for screening of activity limitation and safety awareness (SALSA) in clients affected by leprosy or diabetes. Disability and Rehabilitation 2007;29(9):689-700.
49. Saunderson P, Gebre S, Desta K, Byass P, Lockwood DN. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Leprosy Review 2000;71(3):285-308.
50. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments. International Journal of Leprosy and Other Mycobacterial Diseases 1998;66(2):170-81.
51. Sugumaran DS. Leprosy reactions - complications of steroid therapy. International Journal of Leprosy and Other Mycobacterial Diseases 1998;66(1):10-5.
52. Van Brakel WH, Khawas IB. Nerve function impairment in leprosy: an epidemiological and clinical study - Part 2: Results of steroid treatment. Leprosy Review 1996;67(2):104-18.
53. Van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Leprosy Review 2005;76(3):14-34.
54. Van Brakel WH, Anderson AM, Mutatkar RK, Bakirtzief Z, Nicholls PG, Raju MS, et al. The Participation Scale: measuring a key concept in public health. Disability and Rehabilitation 2006;28(4):193-203.
55. Van Veen NHJ, Schreuders TAR, Theuvenet WJ, Agrawal A, Richardus JH. Decompressive surgery for treating nerve damage in leprosy. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006983.pub2]
56. Walker SL, Roberts CH, Atkinson SE, Khadge S, Macdonald M, Neupane KD, et al. The effect of systemic corticosteroid therapy on the expression of toll-like receptor 2 and toll-like receptor 4 in the cutaneous lesions of leprosy Type 1 reactions. British Journal of Dermatology 2012;167(1):29-35. [PUBMED: 22348338]
57. World Health Organization. WHO Action Programme for the Elimination of Leprosy. A guide to eliminate leprosy as a public health problem. World Health Organization 1995.
58. World Health Organization. WHO Expert Committee on Leprosy [editorial]. World Health Organization Technical Report Series 1998;874:1-43.
59. World Health Organization. WHO Leprosy Elimination Project: Status Report 2003. Geneva: World Health Organization.
60. World Health Organization. Leprosy. http://www.who.int/mediacentre/factsheets/fs101/en/index.html (accessed 27 November 2006).
61. World Health Organization. Global leprosy: update on the 2012 situation. Weekly Epidemiological Record 2013;88(35):365-80.
62. Van Veen NHJ, Meima A, Nicholls PG, Smith WCS, Richardus JH. Corticosteroid interventions for treating nerve damage in leprosy. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005491]
63. Van Veen NHJ, Nicholls PG, Smith WCS, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005491.pub2]